Tarsons Products Q2 FY26: Revenue up, profit falls sharply

EBITDA margin compressionResults View source PDF Explain this filing

TARSONS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.4%Reaction day

₹265.00

prior close

₹263.30

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-4.3% vs market

Medical Equipment & Supplies peers, median of 14sector-0.9%-2.4% vs sector

On the reaction day the stock moved 4.3 pts less than Nifty Microcap 250 and 2.4 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.8

15m

+0.1

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.4+0.9-4.3-0.9-2.4

Next day

-9.6+0.8-10.5-2.5-7.1

-9.4+0.7-10.2-2.7-6.7

-13.6+1.3-14.9-4.3-9.3

-13.2+0.5-13.7-5.1-8.1

-15.5+0.4-15.8-5.1-10.4

-18.2-1.5-16.7-6.4-11.9

15d

-12.3-2.4-9.9-3.9-8.4

-14.0-4.4-9.6-2.2-11.8

-15.1-7.2-7.9-13.9-1.2

-24.3-5.0-19.4-30.0+5.6

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 14Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Tarsons Products Q2 revenue rose 2 percent YoY to Rs 1,023.3M; H1 revenue up 5 percent to Rs 1,936.9M. But consolidated profit after tax fell sharply to Rs 3.3M in Q2 (vs Rs 37.8M YoY) and Rs 60.2M in H1 (vs Rs 219M), about a 73 percent drop. Consolidated EBITDA margins compressed sharply due to higher depreciation and finance costs. Standalone PAT fell about 48 percent in H1 to Rs 101M. Price Waterhouse issued an unmodified limited review report.

Likely market impact

Weak profitability despite revenue growth; sharp PAT decline and margin compression may weigh on the stock. No auditor concerns flagged.